BioPharma APAC - Leading Source of Biopharmaceutical Intelligence in Asia Pacific

China Approves ArkBio Aizhida For ADHD With Rapid Onset And All Day Symptom Control

Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced that China's National Medical Products Administration (NMPA) has approved the...

January 12, 2026 | News

AirNexis Secures Global Rights To Phase 2 COPD Asset AN01 In $200 Million Series A Backed By Frazier And OrbiMed

AirNexis acquires exclusive rights to develop AN01 outside of China from Haisco Pharmaceutical Group Company founded by Frazier Life Sciences, which led...

January 12, 2026 | News

Biocytogen And Acepodia Advance Dual Payload Bispecific ADC Strategy Through Option Based Licensing Pact

Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315) and Acepodia (6976:TT), announced that the companies have entered int...

January 12, 2026 | News

Zai Lab Secures China Approval For AUGTYRO In NTRK Fusion Positive Solid Tumours

-Zai Lab Limited announced that China’s National Medical Products Administration (NMPA) has approved the supplemental New Drug Application (sND...

January 09, 2026 | News

Sichuan Kelun Biotech Secures NMPA IND Approval For SKB105 Antibody Drug Conjugate In Advanced Solid Tumours

Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company", 6990.HK) announced that its Investigational New Drug (IND) appli...

January 07, 2026 | News

Sisram Medical Clears Final Regulatory Step For DAXXIFY Market Entry In China

Marking a Key Milestone Toward Market Launch and Strengthening Sisram's Premium Aesthetics Portfolio Sisram Medical Ltd (the "Company...

January 06, 2026 | News

Harbour BioMed Partners With Lannacheng To Advance Next Generation Radionuclide Drug Conjugates

Harbour BioMed (HKEX: 02142), a global biopharmaceutical company committed to the discovery and development of novel antibody therapeutics in immunolo...

January 02, 2026 | News

Mabwell Doses First Patient Globally In Phase II Trial Of IL 11 Antibody For Pathological Scarring

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that the Phase II clinical trial of i...

January 01, 2026 | News

Senhwa Biosciences Advances CX 5461 Into ADC Combination Trial With Enhertu Backed By US NCI

Senhwa Biosciences has announced a significant clinical milestone with its investigational drug Pidnarulex CX 5461 advancing into a Phase 1...

December 30, 2025 | News

Alphamab Oncology Secures IND Acceptance In China For JSKN033 Phase II Cervical Cancer Study

Alphamab Oncology (Stock Code: 9966.HK) announced that the IND application for a Phase II clinical study of JSKN033 (a proprietary high-concentration subcu...

December 30, 2025 | News

EMA CHMP Backs Gotenfia Golimumab Biosimilar Advancing STADA and Bio Thera European Strategy

Positive opinion from European Medicines Agency supports approval for golimumab biosimilar Gotenfia® developed by Bio-Thera and to be marke...

December 30, 2025 | News

Mabwell Secures US FDA IND Clearance For Anti ST2 Antibody In COPD

Mabwell (688062.SH), an innovation-driven biopharmaceutical company with a fully integrated industry chain, announced that it has received IND clearance fr...

December 26, 2025 | News

China Approves First Dual Immunotherapy Neoadjuvant Regimen For MSI H dMMR Colon Cancer

TABOSUN® (ipilimumab N01 injection) has been approved in combination with TYVYT® (sintilimab injection) for the neoadjuvant treatment o...

December 26, 2025 | News

HKSH Medical Group And Shenzhen Cancer Hospital Formalise Proton Therapy Collaboration Under Healthy China 2030 Framework

In alignment with the national framework for the advancement of proton therapy, facilitated by the National Cancer Center, HKSH Medical Group ("HKSH")...

December 25, 2025 | News

Stay Connected